VBI Vaccines Competitors and Similar CompaniesClear all

VBI Vaccines's competitors and similar companies include PolyPid and Adaptimmune.

	VBI Vaccines VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.	PolyPid PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API).	Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Founding Date	Founding Date 2001	Founding Date 2008	Founding Date 2008
Type	Type Public	Type Public	Type Public
Tags	Tags Healthcare Technology biotech healthtech pharma	Tags Healthcare Technology biotech healthtech pharma	Tags Healthcare Technology biotech healthtech pharma
Locations	Locations Cambridge, US HQ Ottawa, CA Rehovot, IL	Locations Petah Tikva, IL HQ Summit, US	Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB
Employees	Employees 12314% increase	Employees 57	Employees 4007% decrease
Valuation ($)	Valuation ($) 1.9 m	Valuation ($) 23.7 m	Valuation ($) 188.5 m
Financial
Revenue (est.)	Revenue (est.) $8.7m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) $178m (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $70k (FY, 2024)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $178m (FY, 2024)
Net income	Net income ($92.8m) (FY, 2023)	Net income ($34.2m) (FY, 2025)	Net income ($70.8m) (FY, 2024)
Operating ⚠
Patent Applications	Patent Applications N/A	Patent Applications 49 (FY, 2017)	Patent Applications 69 (FY, 2016)
Patents Issued	Patents Issued N/A	Patents Issued 104 (FY, 2017)	Patents Issued 173 (FY, 2016)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 103.8m	Total funding raised $ 107.5m